In conclusion, these studies demonstrate the mechanism by which ghrelin deletion prevents age‐associated hepatic steatosis and suggest that targeting this pathway may offer therapeutic benefit for NAFLD. The gene discussed is GHRL; the disease is metabolic dysfunction-associated steatotic liver disease.